Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 60

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 60
---
 the payment of dividends in the foreseeable future. At present, our policy is to retain earnings, if any, to develop
and market our products and implement our business plan. The payment of dividends in the future will depend upon, among other factors,
our earnings, capital requirements, and operating financial conditions.

<div align='center'>34

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS OF REVIUM RX. AND REVIUM RX LTD.</div>

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. We caution readers regarding certain forward-looking statements in the following discussion and elsewhere herein and any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results, or other developments. Forward-looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties, and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. We disclaim any obligation to update forward-looking statements.

Overview and Recent Developments

We are a pre-clinical biopharmaceutical company
that is principally engaged in development of innovative nano-medicines to deliver advanced treatment solutions for diseases with limited
or no effective treatment options. We focus on creating smarter, more targeted treatments that improve how medicines work in the body,
with the goal of increasing effectiveness while reducing side effects. We are developing advanced lipid-based platforms for a variety
of potential uses, including areas with high unmet-needs such as antimicrobial resistance and solid tumors. Our planned clinical trials
aim to expand the therapeutic horizons of hard-to-treat diseases by amplifying, improving, and unleashing the potential of encapsulated
therapeutics to enhance delivery and achieve a controlled release. This includes antimicrobial resistance and solid tumors being as they
are areas with high unmet need.

We were incorporated on January 24, 1997 as a
Delaware corporation under the name “Fun Cosmetic, Inc.” On August 29, 2005, it changed its name to Grand Canal Entertainment,
Inc. On October 14, 2008, the